Double-blind, Placebo-control, Study to Evaluate the Safety and Pharmacokinetics of CT-044 HCl, in Healthy Volunteers
Double-blinded, Placebo-controlled, Sequential Cohort, Multiple-Dose Escalation Study to Evaluate the Safety and Multiple Dose Pharmacokinetics of CT-044 HCl, a Reactive Species Decomposition Accelerant, in Healthy Human Volunteers
Sponsor: CerSci Therapeutics
A PHASE1 clinical study on Acute Pain and Neuropathy, this trial is ongoing. The trial is conducted by CerSci Therapeutics and has accumulated 8 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Sep 2022 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
May 2020 — Aug 2020 [monthly]
Recruiting PHASE1
-
Feb 2020 — May 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2019 — Feb 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CerSci Therapeutics
- Lotus Clinical Research, LLC
For direct contact, visit the study record on ClinicalTrials.gov .